This is the authors' abstract. We don't add key points for this paper.
Patients with MS have higher risks of outpatient and serious infections compared with patients without MS. The risk of outpatient infections was similarly increased by rituximab and fingolimod and serious infections by rituximab and natalizumab compared with IFN/GLAT. Steps to minimize risks include optimizing bladder care, comorbidity prevention, varicella vaccination, and considering discontinuing or avoiding DMT use in patients with advanced disability and/or previous hospitalizations for infections.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Langer‐Gould et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: